Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Interactions between the cytochrome P450 system and the second-generation antipsychotics.

Trevor I Prior1, Glen B Baker

  • 1Bebensee Schizophrenia Research Unit and Neurochemical Research Unit, Department of Psychiatry, University of Alberta and Alberta Hospital Edmonton, Alta. trevor.prior@amhb.ab.ca

Journal of Psychiatry & Neuroscience : JPN
|April 3, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effects of sodium nitroprusside on the default mode network of patients with schizophrenia and healthy controls.

Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999)·2025
Same author

Impact of D-Amino Acids in Schizophrenia.

Biomolecules·2025
Same author

The Role of Neuroglia in the Development and Progression of Schizophrenia.

Biomolecules·2025
Same author

The Underlying Neurobiological Mechanisms of Psychosis: Focus on Neurotransmission Dysregulation, Neuroinflammation, Oxidative Stress, and Mitochondrial Dysfunction.

Antioxidants (Basel, Switzerland)·2024
Same author

Hikikomori: A Society-Bound Syndrome of Severe Social Withdrawal.

Psychiatry and clinical psychopharmacology·2024
Same author

Chronic pregabalin treatment protects against spreading depolarization and alters hippocampal synaptic characteristics in a model of familial hemiplegic migraine-type 1.

Molecular brain·2023

Understanding cytochrome P450 (CYP) metabolism of second-generation antipsychotics is crucial for managing drug interactions. While clozapine, risperidone, and olanzapine have known CYP pathways, data for quetiapine and ziprasidone remain limited.

Area of Science:

  • Pharmacology
  • Drug Metabolism
  • Biochemistry

Background:

  • The cytochrome P450 (CYP) enzyme system plays a critical role in drug metabolism.
  • Second-generation antipsychotics (SGAs) are widely prescribed for various psychiatric conditions.
  • Understanding the specific CYP enzymes involved in SGA metabolism is essential for predicting and managing drug-drug interactions (DDIs).

Purpose of the Study:

  • To review the known cytochrome P450 (CYP) metabolic pathways for second-generation antipsychotics (SGAs).
  • To highlight the clinical implications of SGA metabolism for drug-drug interaction management.
  • To identify gaps in current knowledge regarding the in vivo metabolism of newer SGAs.

Main Methods:

  • Literature review of studies investigating the metabolism of SGAs by CYP enzymes.

Related Experiment Videos

  • Analysis of reported metabolic pathways for clozapine, risperidone, olanzapine, quetiapine, and ziprasidone.
  • Evaluation of existing in vivo data on drug-drug interactions involving SGAs.

    • Main Results:

    • Clozapine is primarily metabolized by CYP1A2, with contributions from CYP2C19, CYP2D6, and CYP3A4.
    • Risperidone metabolism involves CYP2D6 and CYP3A4.
    • Olanzapine is metabolized by CYP1A2 and CYP2D6, while quetiapine and ziprasidone are metabolized by CYP3A4. Current data suggest minimal impact of these drugs on other medications at standard doses.
    • There is a notable lack of in vivo metabolic data for olanzapine, quetiapine, and ziprasidone.

    Conclusions:

    • Knowledge of SGA metabolism by CYP enzymes is vital for clinicians to anticipate and manage potential drug-drug interactions.
    • While some SGAs have well-characterized metabolic profiles, further in vivo research is needed, particularly for olanzapine, quetiapine, and ziprasidone, to ensure safe and effective therapeutic use.